Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07404865 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
A Phase 3 study of Primary Sjogren's Disease, sponsored by Vor Biopharma.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 250
- Enrollment target
- 3
- Study locations
NCT07404865 is a Phase 3 study of Primary Sjogren's Disease that is actively recruiting participants, run by Vor Biopharma. The registered enrollment target is 250 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT07404865, a Phase 3 study of Primary Sjogren's Disease, is actively recruiting participants, sponsored by Vor Biopharma.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 250 participants
- Enrollment target
- 3
- Study locations
Study Summary
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease (UPSTREAM SjD)
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL Telitacicept
Study Locations (3)
Illinois
- Chicago Clinical Research Institute Inc - Chicago
Louisiana
- Accurate Clinical Research, Inc. - Lake Charles
Texas
- Accurate Clinical Research, Inc. - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2026-02-26 |
| Est. Completion | 2028-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07404865
The ClinicalTrials.gov registry entry for NCT07404865 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vor Biopharma, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Sjogren's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07404865 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Illinois, Louisiana, Texas.
Frequently Asked Questions
What is clinical trial NCT07404865 about?
NCT07404865 is a clinical study titled "Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease". Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease (UPSTREAM SjD)
What is the current status of trial NCT07404865?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2026-02-26. Estimated completion is 2028-08.
What conditions does trial NCT07404865 study?
This clinical trial studies the following conditions: Primary Sjogren's Disease.
What interventions are being tested in trial NCT07404865?
The interventions under investigation include: Placebo (DRUG), Telitacicept (BIOLOGICAL).
Who is sponsoring clinical trial NCT07404865?
This trial is sponsored by Vor Biopharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07404865 being conducted?
This trial has 3 study locations across Illinois, Louisiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Sjogren's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.